A client has a new prescription for diclofenac, a nonsteroidal antiinflammatory drug (NSAID). Which information in the client's history is of greatest concern to the nurse in monitoring the client's response to this medication?

A. Request a prescription to change the route of administration and use the available heparin:
Low molecular weight heparin (LMWH) and unfractionated heparin (UFH) are not interchangeable. LMWH is usually administered subcutaneously, whereas UFH is administered intravenously for acute situations. Changing the route of administration without a new prescription would not be appropriate.

B. Advise the pharmacy of the need to deliver a vial of heparin to the nursing unit immediately:
Since the prescription is for intravenous heparin and the available syringes are of LMWH (which is not suitable for IV use), it is essential to contact the pharmacy to provide the correct formulation. Immediate action ensures that the client receives the correct medication promptly.

C. Calculate and administer the equivalent dose of the available low molecular weight heparin:
Calculating and administering LMWH instead of UFH is inappropriate because they are different types of heparin with different indications, dosing regimens, and routes of administration. Using LMWH for an IV prescription could result in ineffective treatment or complications.

D. Dilute the available heparin in 250 mL of normal saline solution prior to IV administration:
LMWH should not be diluted or used in place of UFH for IV administration. This action is incorrect because the available medication is not suitable for the prescribed route and dose. The proper medication needs to be obtained from the pharmacy.

A. High density lipoprotein (HDL):
HDL levels are important for cardiovascular health as higher levels are associated with a lower risk of coronary artery disease. However, atorvastatin primarily targets LDL levels. While increasing HDL is beneficial, it is not the primary measure of atorvastatin's effectiveness.

B. Low density lipoprotein (LDL):
Atorvastatin is a statin medication used to lower LDL cholesterol levels, which is a major risk factor for coronary artery disease. A decrease in LDL levels indicates that the medication is having its desired effect, reducing the risk of cardiovascular events.

C. Creatine phosphokinase (CK):
CK levels are monitored to assess muscle damage or side effects related to statin use, such as rhabdomyolysis. While important for safety monitoring, changes in CK levels do not directly reflect the effectiveness of atorvastatin in managing cholesterol levels.

D. Prothrombin time (PT):
PT is used to evaluate blood clotting ability and is not directly related to the effectiveness of atorvastatin. It is more relevant for monitoring anticoagulant therapy rather than statin therapy for cholesterol management.